Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
← catalyst calendarSponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →. With National Institutes of Health (NIH).
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
102estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-10-26 | actual | When the study began enrolling |
| Primary completion | Jul 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2020-09-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Central Nervous System Neoplasms
- Glioblastoma
- Gliosarcoma, Adult
- Anaplastic Oligodendroglioma
- Anaplastic Astrocytoma
- Pilocytic Astrocytoma
- Oligodendroglioma
- Gliomatosis Cerebri
- Pleomorphic Xanthoastrocytoma
- Anaplastic Pleomorphic Xanthoastrocytoma
- Diffuse Midline Glioma, H3 K27M-Mutant
- Ependymoma
- Ependymoma, Anaplastic
- Medulloblastoma
- Teratoid Rhabdoid Tumor
- Neuroectodermal Tumors, Primitive
- Neuroectodermal Tumors
- Anaplastic Meningioma
- Atypical Meningioma
- Choroid Plexus Neoplasms
- Pineal Tumor
- Diffuse Astrocytoma
- Glial Tumor
Intervention
- Drug: ONC206
Primary outcomes
what the primary-completion date above is the date OFMaximum Tolerated Dose (MTD) of single-agent, oral ONC206
measured 28 Days
Number of Participants who Experienced Dose-Limiting Toxicities (DLTs)
measured 28 Days
Publications
- PMID 35417530 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed